Innate Pharma (IPHYF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 12-2024 | 12-2023 | 06-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -24,230 | -53,533 | -8,193 | 1,873 | -61,217 |
| Depreciation Amortization | 803 | 2,158 | 5,510 | 3,975 | 47,839 |
| Accounts receivable | -3,050 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -4,502 | N/A | N/A | N/A | N/A |
| Other Working Capital | -16,090 | 42,377 | -34,732 | -20,205 | -13,172 |
| Other Operating Activity | 11,693 | 1,536 | 2,177 | 1,856 | 6,369 |
| Operating Cash Flow | $-35,377 | $-7,462 | $-35,238 | $-12,501 | $-20,181 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 8,109 | N/A | N/A | N/A | N/A |
| PPE Investments | -66 | -423 | -218 | -337 | -564 |
| Other Investing Activity | -126 | 10,378 | 22,547 | 69 | 2,542 |
| Investing Cash Flow | $7,917 | $9,955 | $22,329 | $-268 | $1,978 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -5,059 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 16,951 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 0 | -6,501 | -2,128 | -1,359 | -1,926 |
| Financing Cash Flow | $11,892 | $-6,501 | $-2,128 | $-1,359 | $-1,926 |
| Exchange Rate Effect | 1,160 | -546 | 297 | 158 | -451 |
| Beginning Cash Position | 75,373 | 76,402 | 91,157 | 91,839 | 109,317 |
| End Cash Position | 60,965 | 71,847 | 76,416 | 77,870 | 88,739 |
| Net Cash Flow | $-14,408 | $-4,555 | $-14,741 | $-13,969 | $-20,578 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,377 | -7,462 | -35,238 | -12,501 | -20,181 |
| Capital Expenditure | -66 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -35,443 | -7,462 | -35,238 | -12,501 | -20,181 |